Skip to main content

NuGenerex Immuno-oncology, Inc. (NGIO)

NuGenerex Immuno-oncology will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.50 - $9.50
Current IPO price range
Chart not available yet
Market Cap952.70M
Revenue (ttm)n/a
Net Income (ttm)-4.63M
Shares Out105.86M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About NGIO

NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme...

IndustryPharmaceutical Preparations
IPO DatePending
CEOJoseph Moscato
Employees6
Stock ExchangeNASDAQ
Ticker SymbolNGIO
Full Company Profile

Financial Performance

Financial Statements

News

NuGenerex Immuno-oncology IPO Registration Document (S-1)

NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC